NCT03444922

Brief Summary

The National Institutes of Health has encouraged research examining effects of BPA, yet evidence in humans evaluating the effects of BPA on insulin and glucose concentrations remains exclusively associative in nature. Thus, the primary purpose of this study is to determine whether an acute oral ingestion of BPA impacts insulin and glucose concentrations, and other endocrine factors (Pro-insulin, C-Peptide, Estrogen, triglycerides). Findings from this pilot study will inform public health recommendations for food packaging and provide much needed experimental evidence as to whether BPA poses any public health risk.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
11

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2016

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2016

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

February 8, 2018

Completed
18 days until next milestone

First Posted

Study publicly available on registry

February 26, 2018

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 14, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 14, 2019

Completed
Last Updated

February 18, 2019

Status Verified

February 1, 2019

Enrollment Period

2.5 years

First QC Date

February 8, 2018

Last Update Submit

February 14, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change From Baseline Glucose at 180 Minutes

    Glucose concentrations will be assessed before and in response to a 75 gram Oral Glucose Tolerance Test

    9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180

Secondary Outcomes (5)

  • Change From Baseline Insulin at 180 Minutes

    9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180

  • Change From Baseline Estrogen at 180 Minutes

    9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180

  • Change From Baseline C-Peptde at 180 Minutes

    9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180

  • Change From Baseline Pro-Insulin at 180 Minutes

    9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180

  • Change From Baseline Triglycerides at 180 Minutes

    9 samples over 3 hours at time minutes 0 (baseline), 15, 30, 45, 60, 90, 120, 180

Study Arms (3)

Placebo

PLACEBO COMPARATOR

Participants consume Vanilla Wafer cookie

Other: Placebo

BPA 4 ug/kg BW

EXPERIMENTAL

Participants consume 4 ug/kg BW of BPA on a Vanilla Wafer Cookie

Other: BPA 4 ug/kg BW

BPA 50 ug/kg BW

EXPERIMENTAL

Participants consume 50 ug/kg BW of BPA on a Vanilla Wafer Cookie

Other: BPA 50 ug/kg BW

Interventions

PlaceboOTHER

Ingestion of Placebo

Placebo

Oral BPA ingestion of 4 ug/kg BW

BPA 4 ug/kg BW

Oral BPA ingestion of 50 ug/kg BW

BPA 50 ug/kg BW

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • BMI = 18.5-35
  • Age 18-50 years
  • Non-smoking
  • English speaking

You may not qualify if:

  • History of infertility
  • Type 2 or Type 1 diabetes
  • Cardiovascular disease, or any other metabolic disease/complication
  • Hypertension (systolic blood pressure ≥140, diastolic blood pressure ≥90) assessed by sphygmomanometer
  • History of major psychiatric illness, drug abuse, or unsafe dieting practices
  • History of bariatric surgery
  • Pregnant women or women expecting or trying to become pregnant
  • Participating in other studies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

California Polytechnic State University

San Luis Obispo, California, 93405, United States

Location

Study Officials

  • Todd Hagobian, PhD

    California Polytechnic State University-San Luis Obispo

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Double-blinded study; Study statistician computer generated randomization
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

February 8, 2018

First Posted

February 26, 2018

Study Start

September 1, 2016

Primary Completion

February 14, 2019

Study Completion

February 14, 2019

Last Updated

February 18, 2019

Record last verified: 2019-02

Data Sharing

IPD Sharing
Will not share

No plan to share data in this pilot study

Locations